PsyMed Ventures is a venture capital firm based in San Francisco, California, specializing in early-stage investments in the psychedelics sector. Founded in 2020 by Matias Serebrinsky and Dina Burkitbayeva, the firm focuses on innovative areas such as psychedelic medicine, neurotechnology, human augmentation, precision psychiatry, and digital therapeutics. By targeting these emerging fields, PsyMed Ventures aims to support the development of groundbreaking solutions that can transform mental health treatment and enhance human well-being.
Jimini Health is a mental health company dedicated to enhancing the effectiveness of mental health care globally. Established in 2023 by a team of experienced professionals in AI, biotech, and psychology, Jimini combines teletherapy with personalized AI support to create a comprehensive care model. Patients receive assistance from licensed clinicians and an AI therapy assistant named Sage, who work collaboratively to help individuals achieve their mental health goals. Jimini emphasizes the importance of clinical oversight and safety, ensuring that its technology is purpose-built and rooted in scientific principles. The company focuses on evidence-based practices and individualized care, particularly for those experiencing persistent anxiety. By integrating advanced technology with expert clinical guidance, Jimini aims to deliver high-quality mental health experiences that empower patients to take proactive steps in their treatment.
Motif Neurotech
Series A in 2024
Motif Neurotech develops minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. The company focuses on wireless power and data technologies, which facilitate the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. These innovative implants enable patients to repair neural circuits through electronic therapies, offering a promising approach to address complex mental health challenges.
Motif Neurotech
Seed Round in 2023
Motif Neurotech develops minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. The company focuses on wireless power and data technologies, which facilitate the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. These innovative implants enable patients to repair neural circuits through electronic therapies, offering a promising approach to address complex mental health challenges.
Journey Clinical
Series A in 2023
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
Delix Therapeutics
Series A in 2021
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.
Journey Clinical
Seed Round in 2021
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.